SCHEMBL3043264

SCHEMBL3043264

CN1CCC(N(C)C(=O)CCC(=O)c2ccc(-c3ccccc3)cc2)CC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 1/20 0.62
POLB P06746 2/20 0.56
LMNA P02545 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
CCR5 P51681 1/20 0.50
SCN1A P35498 1/20 0.50
SCN2A Q99250 1/20 0.50
SCN3A Q9NY46 1/20 0.50
CYP3A4 P08684 1/20 0.50
USP30 Q70CQ3 1/20 0.49
HTR2A P28223 1/20 0.49
HTR2C P28335 1/20 0.49
KMT2A Q03164 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
FFAR1 O14842 1/20 0.48
CYP1A2 P05177 1/20 0.48
RAB9A P51151 1/20 0.48
HIF1A Q16665 1/20 0.48
PKM P14618 1/20 0.47
HPGD P15428 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3048764 0.81 CCR5 (0.71) MCHR1POLBCCR5KMT2A
Hydrochloric Acid SCHEMBL3035507 0.80 CCR5 (0.70) MCHR1POLBCCR5KMT2A
SCHEMBL14500762 0.76 MCHR1 (0.52) MCHR1POLBLMNAL3MBTL1CYP3A4
SCHEMBL13452963 0.76 KMT2A (0.58) MCHR1POLBLMNAHTR2AHTR2C
SCHEMBL16222294 0.75 PKM (0.53) MCHR1POLBLMNAL3MBTL1CCR5
SCHEMBL3034628 0.75 ALDH1A1 (0.55) LMNAL3MBTL1SMN1; SMN2RAB9AHIF1A
SCHEMBL3042580 0.75 HRH3 (0.50) MCHR1POLBLMNACCR5HTR2A
SCHEMBL12359048 0.75 CCR5 (0.69) POLBCCR5KMT2A
SCHEMBL9877244 0.74 SMN1; SMN2 (0.64) LMNAL3MBTL1CYP3A4KMT2ASMN1; SMN2
SCHEMBL2925897 0.74 POLB (0.57) MCHR1POLBLMNAL3MBTL1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1434765-B1 SUBSTITUTED PIPERIDINES WITH SELECTIVE BINDING TO HISTAMINE H3-RECEPTOR HIGH POINT PHARMACEUTICALS LLC (US) 2009-12-02 EP claimed
US-20100222386-A1 SUBSTITUTED PIPERIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-02 US disclosed
US-20100222386-A1 SUBSTITUTED PIPERIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-02 US disclosed
US-20100222386-A1 SUBSTITUTED PIPERIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-02 US disclosed
US-7767695-B2 Substituted piperidines HIGH POINT PHARMACEUTICALS, LLC (US) 2010-08-03 US disclosed
US-7767695-B2 Substituted piperidines HIGH POINT PHARMACEUTICALS, LLC (US) 2010-08-03 US disclosed
US-7767695-B2 Substituted piperidines HIGH POINT PHARMACEUTICALS, LLC (US) 2010-08-03 US disclosed
EP-1434765-B1 SUBSTITUTED PIPERIDINES WITH SELECTIVE BINDING TO HISTAMINE H3-RECEPTOR HIGH POINT PHARMACEUTICALS LLC (US) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222386-A1 SUBSTITUTED PIPERIDINES HRH3, HRH4, HRH2 MCHR1 307/4885POLB 3476/4885LMNA 3641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.